access, dialysis. See vascular access
ACE inhibitors. 43
acute myocardial infarction (AMI)
mortality and 37
admission rates. See hospitalization;
admission rates
anemia. See erythropoietin therapy;
hemoglobin
anemia treatment
dialysis unit affiliation and 167
hemoglobin levels 75
hemoglobin levels and 27, 91, 92
at initiation 75
iron therapy 92
in pediatric patients 136
angiography 151, 152
angioplasty 99, 108
angiotensin receptor blockers
(ARBs) 43
antibody induction medications 123
antimetabolites 123
arythmia 142
arteriovenous fistulas
placement rates 39
arteriovenous grafts
placement rates 39
atherosclerotic heart disease
(ASHD). See cardiovascular
disease
mortality and 37
bacteremia/septicemia
hospitalization and 104, 105
in pediatric patients 142
vascular access and 99
Bayesian hospitalization ratios 172
Bayesian mortality ratios 172
bypass, coronary 108
Calcijex 170
calcineurin inhibitors 123
calcium/phosphorus testing 168
CAPD. See dialysis
cardiac arrest. See cardiovascular
disease
cardiorenal disease
diabetes and 52–55
diagnosis & testing 150–153
expenditures and 179
glomerulonephritis and 52, 53,
54, 55
hospitalization and 28, 54, 55, 104,
105, 108, 142, 143, 179
hypertension and 52–55
mortality and 37, 46, 51–53, 58, 59,
109, 143
in pediatric patients 142, 143
catheters 56, 57, 73, 74, 98, 99, 108,
139, 171, 184. See also vascular
access
placement rates 39
CBC testing 169
CCPD. See dialysis
cellulitis 104
cholesterol 134
at initiation 76
chronic kidney disease
dietitian care and 38
expenditures 21, 91, 177
nephrologist care and 38
pre-ESRD counseling and 38
preventive care and 38, 43, 47
Comprehensive Dialysis Study (CDS)
114, 155–159
congestive heart failure (CHF). See
also cardiovascular disease
expenditures 21
hospitalization and 142
mortality and 37
in pediatric patients 142
counts, patient. See incidence;
predilection; transplantation
CPM data 91, 98, 99
creatinine, serum
at initiation 76
cystic kidney disease
hospitalization and 140
at initiation 36
modality and 82, 84
patient counts 22, 65, 67
rates of ESRD due to 22, 65, 67
transplantation and 40
death. See mortality
decloth procedures 99
diabetes
cardiovascular disease and 52–55
comprehensive monitoring 183
congestive heart failure and 21, 91
ESRD networks and 68
expenditures 21, 91, 180
in the general population 36
hospitalization and 54, 55
infection and 52–55
at initiation 36
at initiation 191
international comparisons 191
microalbumin testing 44
modality and 82, 84
monitoring, recommended 91, 96
mortality and 52, 53, 58
patient counts 22, 65, 67
prescription drug therapy and 43
preventive care 43, 91, 96, 170
rates of ESRD due to 22, 42, 47,
55, 67, 68
recommended monitoring 170
survival and 107
transplantation and 40
transplant wait list and 40
dialysis
adequacy 27, 91
ESRD network populations 69
expenditures 30, 31, 178, 180, 182
hospitalization and 28, 104, 105,
140
infection and 104, 105
international comparisons 193
mortality and 29, 103, 106
patient counts
incident 22, 23, 24, 43, 51, 84
pediatric 22, 82, 84, 133
prevalent 22–24, 43
patient rates
incident 22, 24, 25, 82, 83
pediatric 22, 82, 84
prevalent 22, 24, 84, 85
patients returning from transplant
23, 125
patients starting or restarting 23
survival and 22, 105, 140, 141
dialysis unit affiliation
time changes over time 163, 164
clinical monitoring and 168, 169
erythropoietin (EPO) treatment
hemoglobin levels and 166
hospitalization ratios and 172, 173
iron therapy and 167
modality and 82, 84
mortality ratios and 172, 173
patient counts and 164
preventive care and 170
time managed 164
transfusions and 167
unit counts and 164
vascular access and 171
vitamin D therapy and 170
dialysis unit location 165
dialysis withdrawal from 110, 111
dietitian care, pre-ESRD 38, 134
drug therapy, prescription 43
hospitalizations 31
ECD kidneys 121
ECGs 151, 152
echocardiograms 151, 152
erythropoiesis stimulating agent
(ESA) expenditures 31, 177, 181
at initiation 75
in pediatric patients 135
pre-ESRD use 26
erythropoietin (EPO) therapy, See
also anemia treatment
expenditures 177, 181, 182
in pediatric patients 136
weekly 136
erythropoietin therapy
hemoglobin levels and 92
weekly dose 92
ESRD networks
HP2010 objectives and 46, 47
patient counts, growth in 68, 69
providers and 164
expected remaining lifetimes 106
expenditures. See also Medicare
commissions actual and predicted costs 185
before and after initiation 31
CKD 21, 91
ESAs 177
ESRD 21, 30, 31, 91
injectables 31
inpatient 180
non-Medicare 178
outpatient 180
physician/supplier 180
during transition to ESRD 179
eye examinations, diabetic 91, 96,
170, 183
eye exams, diabetic 43, 46
ferritin testing 169
Ferrlecit 167
fistulas, arteriovenous 56, 57, 73, 74,
91, 98, 103, 130, 171, 184.
See also vascular access
glomerular filtration rate (eGFR)
at initiation 74, 76, 77
hemodialysis,home 86, 87
glomerular filtration rate, estimated
(eGFR)
at initiation 135
in pediatric patients 135
hemodialysis
ESRD networks and 68
hospitalization and 54, 55, 140
at initiation 36
modality and 82, 84
mortality and 32, 53
patient counts 22, 65, 67
rates of ESRD due to 22, 65, 67, 68
survival and 107
transplantation and 40
hemoglobin
anemia treatment and 91, 92, 167
hemodialysis unit affiliation and 166, 167
EPO dose and 27, 92
ESA treatment and 75
at initiation 75
at initiation 75, 76, 77, 135
at initiation 74
monthly 27, 92, 136
overshooting of target levels 91, 95,
137, 166
patient distribution and 27, 92
patient distribution by 77
in pediatric patients 135-137
pre-ESRD nephrologist care and 74
target levels 91
undershooting of target levels 94,
137, 166
hepatitis B vaccinations 91, 97, 138,
170
hospice care 110, 111
hospitalizations admission rates 104, 105, 108, 140
all-cause 28, 104, 105, 140, 142, 179
for bacteremia/sepsis 104, 105
142, 146
cardiovascular disease 143
cardiovascular disease and 28, 54,
55, 108, 142, 179
cause-specific 28, 108
for cellulitis 104, 105
diabetes and 54, 55
dialysis unit affiliation and 172, 173
expenditures 179
glomerulonephritis and 54, 55
hospitals 104, 140
hypertension and 54, 55
infection and 28, 54, 55, 108, 142,
143
modality and 104, 105
in pediatric patients 105, 140,
142, 143
for peritonitis 105
for pneumonia 104, 105, 142
ratios 172, 173
targets 172, 173
vascular access and 28, 104, 105,
108, 142
hypertension
ESRD networks and 68
hospitalization and 54, 55
at initiation 36
modality and 82, 84
mortality and 52, 53
patient counts 22, 65, 67

survival.

revascularization prevalence vaccinations lipid testing guidelines diabetic international comparisons patient rates modality and 22, 24, 25, 84, 85 patient counts 22, 24, 5, 63, 6, 67, 81, 84 pediatric 22, 66, 84, 133 unit affiliation and 164 patient rates 22, 24, 25, 66, 67, 84, 189 pediatric 22, 66, 84 international comparisons 189, 192 primary diagnosis and 22, 67 projections 63 prevalence of ESRD international comparisons 192 prevent care

in CKD patients 38, 43, 47 diabetic 43, 91, 96, 170 expenditures 183 guidelines 91, 96 lipid testing 91 in pediatric patients 138 vaccinations 45, 47, 91, 97, 170 projections of ESRD counts and costs through 2020 63
tacrolimus 123 transplants, blood 27, 93, 167 transplantation cardiovascular disease and 125, 127 counts 119, 122, 126 DCD kidneys 122 delayed graft function 124 dialysis, return to 125 donors 119, 122 ECD kidneys 121, 122 ESRD network populations 69 expenditures 30, 178–180 graft failure 124 graft survival 125, 127 hospitalization and 28, 104, 105, 140 immunosuppression 123, 127 infection and 125, 127 international comparisons 194, 195 malignancy and 125, 127 mortality and 22, 29, 103, 106, 121, 125, 127 outcomes after 124 outcomes after listing 121 patient counts incident 22, 24, 63, 81, 82 pediatric 22, 82, 84, 133 prevalent 22, 24, 63, 81, 84 patient rates incident 22, 24, 25, 82 pediatric 22, 82, 84 prevalent 22, 24, 25, 84 patients returning to dialysis from 23 in pediatric patient 127 in pediatric patients 126 primary non-function 124 projections 63

deficiency and 107 in pediatric patients 140, 141 in transplant patients 29, 124

rates 122, 126 retransplantation 125 survival and 29, 107, 140, 141 wait list for 24, 40, 46, 63, 81, 120, 126 wait time for 24, 120, 126 within three years of registration 41, 46
transplant options, pre-ESRD information on 38 triglycerides 134 at initiation 76 units. See dialysis unit affiliation urea reduction ratio (URR) 27, 91 vaccinations 45, 47, 91, 96, 138, 170, 183 vascular access current access 39, 46, 91, 98, 99 dialysis unit affiliation and 171 events and complications 99 expenditures 184 first access 39, 91 first-year 56, 57 hospitalization and 28, 104, 105, 108, 142 infection and 104, 139, 142 at initiation 26, 56, 57, 73, 74, 139 in pediatric patients 139 nephrologist care and 74 in pediatric patients 142 placement, probability of 56 placement rates 57 pre-ESRD nephrologist care and 26 Venofor 167 vintage, patient mortality and 29, 103, 107 vitamin D hormone expenditures 31, 104, 182 use of 170

Zemplar 170

ESRD use 75, 135 nephrologist care 38, 46, 74, 134 prevalence diabetes and 67 ESRD network populations 69 mean age and 68 median age and 67 modality and 22, 24, 25, 84, 85 patient counts 22, 24, 63, 66, 67, 81, 84 pediatric 22, 66, 84, 133 unit affiliation and 164 patient rates 22, 24, 25, 66, 67, 84, 189 pediatric 22, 66, 84 international comparisons 189, 192 primary diagnosis and 22, 67 projections 63 prevalence of ESRD international comparisons 192 prevent care in CKD patients 38, 43, 47 diabetic 43, 91, 96, 170 expenditures 183 guidelines 91, 96 lipid testing 91 in pediatric patients 138 vaccinations 45, 47, 91, 97, 170 projections of ESRD counts and costs through 2020 63
tacrolimus 123 rates, disease. See incidence; prevalenct; transplantation recombinant growth hormone 131, 144, 145 revascularization 151, 153 stents, coronary 108 steroids 125 stress testing 151, 152 survival. See also mortality